Clinical trials
Platinum-sensitive Ovarian Cancer clinical trials
Below are recruiting platinum-sensitive ovarian cancer clinical trials, each written for real people, not researchers. We’re tracking 32 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06560112RecruitingPhase 2
Combination therapy trial for recurrent ovarian cancer
This trial tests two experimental drugs, AK104 and AK112, for ovarian cancer that has come back after standard platinum chemotherapy. It may be an option if your cancer is a high-grade type and you have had prior treatment.
ShanghaiAges 18 years+ - NCT07286240RecruitingPhase 2
QL1706 with chemo and anlotinib for recurrent ovarian cancer
This trial tests a combination of a new immunotherapy drug (QL1706), chemotherapy, and a targeted therapy (anlotinib) for ovarian cancer that has come back after standard platinum treatment. The goal is to see if this triple therapy can shrink tumors or slow the cancer's return.
Guangzhou, GuangdongAges 18–70 - NCT07743164RecruitingPhase 3
Raludotatug deruxtecan for PARP-inhibitor-resistant ovarian cancer
This trial tests a new drug called raludotatug deruxtecan (with or without bevacizumab) for people with ovarian cancer that has grown despite PARP inhibitor maintenance treatment. The goal is to see if this drug can shrink tumors or slow the cancer's growth.
Fountain Valley, CaliforniaAges 18 years+ - NCT06843447RecruitingPhase 1/Phase 2
Study of raludotatug deruxtecan for ovarian cancer
This study tests a new drug called raludotatug deruxtecan for people with certain types of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The drug is designed to target and kill cancer cells while sparing healthy tissue. It may be used alone or with other treatments, depending on the study group.
New Haven, ConnecticutAges 18 years+ - NCT06906341RecruitingPhase 2
Relacorilant combo for gynecologic cancers
This trial tests a drug called relacorilant combined with different treatments for ovarian, fallopian tube, primary peritoneal, or endometrial cancers. It may help patients whose cancer has stopped responding to standard therapies.
Birmingham, AlabamaAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06540729RecruitingPhase 2
Combination treatment for ovarian clear cell cancer
This trial tests a combination of three drugs (RC48, AK104, and bevacizumab) for ovarian clear cell carcinoma, a type of ovarian cancer. The goal is to see if this combination can help shrink or control the cancer in people who have not had many prior treatments.
Guanzhou, GuangdongAges 18–75 - NCT06971744RecruitingPhase 2
Study of autophagy maintenance for ovarian cancer
This trial tests whether a combination of medications (hydroxychloroquine, everolimus, and others) can help keep ovarian cancer from coming back after successful platinum chemotherapy plus Avastin. It is for people whose cancer responded well to their most recent chemo and who can continue Avastin maintenance.
Charleston, South CarolinaAges 18 years+
Hear when a new Platinum-sensitive Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for platinum-sensitive ovarian cancer?
- Yes. Clin2 currently lists 32 recruiting platinum-sensitive ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a platinum-sensitive ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a platinum-sensitive ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.